Some unsolicited advice, page-7

Unfortuantely after too many trials to mention and probably close to 60 million spent on BIT225, the compound has failed to provide conclusive evidence. A failure to treat COVID in humans, BIT225-011 provided sub-par results which provided no further insight into effectiveness and BIT225-010 was still well short of expectations in providing conclusive evidence. The company even finally admitted that there are no assays to even show the drug is clearing out virus in reservoirs after undergoing a second round of Phase 2. It's been a good experimental drug to create hype through carrot dangling and keeping scientists in jobs, however from a commercial aspect all trials have lead to a dead end.

Big Pharma are extremely risk adverse and to take on an experimental drug requires conclusive evidence. Question now ... are shareholders so foolish to believe that another single woman working from home aka. C14 Consulting Group can find a deal and save the day based on the sub par trial results? Afterall hasn't MM and Hoy been spruiking a deal for the last 10 years?

I agree shareholders need to find a way to remove the entire board and finally rid itself of MM .... if BIT225 showed some commercial promise. However a mess has been left from a clinical prespective. More expensive trials will be needed for BIT225 and there is simply no way any funds raised will be enough to benefit clinical activities apart from a basic animal model starting from scratch with HBV. If this was a game of snakes and ladders we have slid back to the start on the back of slimey management.

Common sense tells us the type of money this company aiming to raise will simply be a flushed down the toilet on staff wages without progressing any other clinical measures and will be back here in 6 months with a worse SP and close to zero bank balance yet again. Shareholders would be best to cut their losses and sell while they can rather than chip in another cent.